- Correction
- Open access
- Published:
Correction to: L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fbrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
Respiratory Research volume 24, Article number: 228 (2023)
The Original Article was published on 06 September 2023
Correction to: Stefania et al. Respiratory Research (2023) 24:217
Following publication of the original article [1], the authors identified an error in the authors name.
The given name and family name of all authors name were erroneously transposed.
The incorrect author name is: Lo Cicero Stefania1†, Castelli Germana1†, Blaconà Giovanna2, Bruno Sabina Maria2, Sette Giovanni1, Pigliucci Riccardo1, Villella Valeria Rachela3,4, Esposito Speranza3,4, Zollo Immacolata3,4, Spadaro Francesca5, De Maria Ruggero6,7, Biffoni Mauro1, Cimino Giuseppe8, Amato Felice3,4, Lucarelli Marco2,9† and Eramo Adriana1*†
The correct author name is: Stefania Lo Cicero1†, Germana Castelli1†, Giovanna Blaconà2, Sabina Maria Bruno2, Giovanni Sette1, Riccardo Pigliucci1, Valeria Rachela Villella3,4, Speranza Esposito3,4, Immacolata Zollo3,4, Francesca Spadaro5, Ruggero De Maria6,7, Mauro Biffoni1, Giuseppe Cimino8, Felice Amato3,4, Marco Lucarelli2,9 and Adriana Eramo1*
The author group has been updated above and the original article [1] has been corrected.
References
Stefania LC, Germana C, Giovanna B, et al. L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient–derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients. Respir Res. 2023;24:217. https://doi.org/10.1186/s12931-023-02516-0
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12931-023-02516-0
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Lo Cicero, S., Castelli, G., Blaconà, G. et al. Correction to: L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fbrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients. Respir Res 24, 228 (2023). https://doi.org/10.1186/s12931-023-02535-x
Published:
DOI: https://doi.org/10.1186/s12931-023-02535-x